|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,333,992: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,333,992, granted on December 18, 2012, to the University of California, covers a novel method for treating various diseases using a specific composition involving a 5-HT1A receptor agonist. The patent's scope primarily relates to pharmaceutical formulations and methods for modulating serotonergic pathways, with particular emphasis on treating psychiatric disorders such as depression, anxiety, and schizophrenia. This analysis dissects the scope of claims, their biological and chemical specificity, and situates the patent within the broader landscape of serotonergic agents and neuropharmacology patents.
What is the Scope of U.S. Patent 8,333,992?
Core Invention
The patent claims protection over a method of treating neuropsychiatric disorders using a compound that acts as a selective 5-HT1A receptor agonist, with specific formulations and dosing regimens. It also encompasses pharmaceutical compositions comprising the active agents, as well as methods of synthesis.
Principal Claim Types
- Method Claims: Cover therapeutic methods for treating specific disorders (e.g., depression, anxiety) with the agonist.
- Composition Claims: Cover pharmaceutical formulations, including dosages and excipients.
- Use Claims: Pertains to the clinical utility of the compound in treating neuropsychiatric conditions.
Scope of Claims Breakdown
| Claim Type |
Focus |
Key Elements |
Geographical/Legal Coverage |
| Method Claims |
Therapeutic application |
Administration of compound X (e.g., gepirone, 8-OH-DPAT) |
U.S. |
| Composition Claims |
Pharmaceutical formulation |
Specific ratios, dosages, pharmaceutical carriers |
U.S. |
| Use Claims |
Indication-specific |
Treatment of disorders like depression, anxiety |
U.S. |
Claim Examples (Simplified)
- Claim 1: A method of treating a neuropsychiatric disorder by administering a therapeutically effective amount of a 5-HT1A receptor agonist.
- Claim 2: The method of Claim 1, wherein the 5-HT1A receptor agonist is gepirone or a derivative thereof.
- Claim 3: A pharmaceutical composition comprising a 5-HT1A receptor agonist and a pharmaceutically acceptable carrier.
- Claim 4: Use of the composition in the treatment of depression.
Biological and Chemical Specificity of Claims
Active Compounds Covered
- Gepirone: An anxiolytic and antidepressant agent, selective 5-HT1A receptor partial agonist.
- Other Derivatives: Structural analogs of gepirone with similar receptor activity.
- Dosing Regimens: Specific administration schedules aimed at optimizing therapeutic outcomes.
Chemical Definition
The patent emphasizes derivatives of gepirone and related molecules, with specific functional groups conferring selectivity for 5-HT1A receptors. The claims do not broadly cover all serotonergic agents but are tailored toward compounds with demonstrated receptor activity.
Receptor Specificity
- 5-HT1A: Targeted receptor subtype known for its role in anxiolytic and antidepressant effects.
- Selectivity Claims: The patent emphasizes compounds with high selectivity, minimizing off-target effects associated with other serotonergic receptors (e.g., 5-HT2A).
Scope of Chemical Variations
The claims include:
- Structural analogs within a specific chemical genus.
- Prodrugs and metabolites with similar receptor activity.
- Formulations with controlled-release or combination therapies.
Patent Landscape for 5-HT1A Receptor Agonists and Related Drugs
Historical Context
- The use of 5-HT1A receptor agonists dates back to early research in the 1980s.
- Approved drugs like buspirone (1979) — a first-line treatment for anxiety with 5-HT1A partial agonist activity — underpin the therapeutic rationale.
- Gepirone, similar to buspirone, received FDA approval in some jurisdictions, but its patent landscape is complex.
Key Patents and Patent Families
| Patent/Application |
Filing Date |
Applicant |
Focus |
Status |
Relevance |
| US Patent 4,407,772 |
1981 |
Bristol-Myers Squibb |
Buspirone analogs |
Expired |
Early serotonergic agents |
| US Patent 7,097,036 |
2005 |
GlaxoSmithKline |
Gepirone formulations |
Expired |
Formulation technology |
| US Patent 8,333,992 |
2008 |
University of California |
Specific method for treating disorders |
Active |
Core focus of current analysis |
Overlap and Differentiation
- The patent’s claims focus on specific compounds and treatment regimens, differentiated from broad claims on serotonergic agents.
- It exists alongside other patents on related compounds and activation methods for serotonergic receptors.
Patent Expiry Timeline
- Many pertinent patents related to gepirone and similar agents expire or are nearing expiration (e.g., USP 7,097,036 in 2023), opening opportunities for generic development.
Patent Thickets
- The landscape includes multiple overlapping patents, especially on chemical derivatives, formulations, and methods of use.
- Companies often pursue composition, method, and use patents in tandem to extend market exclusivity into new indications or formulations.
Comparison with Related Therapeutics and Patents
| Attribute |
U.S. Patent 8,333,992 |
Buspirone (US Patent 4,407,772) |
Gepirone (US Patent 7,097,036) |
Buspirone & Gepirone Analogues |
| Focus |
Specific treatment methods and compounds |
Broad serotonergic agents |
Formulations and uses |
Structural analogs, formulations |
| Receptor Target |
5-HT1A receptor |
5-HT1A partial agonist |
5-HT1A receptor |
Similar mechanisms |
| Indications |
Depression, anxiety |
Anxiety, panic |
Depression, anxiety |
Varied psychiatric disorders |
| Patent Status |
Active |
Expired |
Expired |
Expiring/expired |
| Claims Specificity |
Narrow (methods/formulations) |
Broad |
Narrow (formulations) |
Varies |
Why is U.S. Patent 8,333,992 Significant?
- It consolidates a method of treatment that can be employed with select 5-HT1A agonists.
- It emphasizes patient-specific dosing and formulations, aligning with personalized medicine trends.
- Its scope overlaps with existing drug development, but with specific claims that could limit competitors' use of similar compounds or methods.
How Does This Patent Fit Within the Broader Serotonergic Landscape?
Precedent and Innovation
- Builds upon decades of serotonergic pharmacology.
- Focuses on selective receptor targeting for psychiatric indications.
- Represents an incremental innovation, with claims that mitigate certain prior art but are still susceptible to challenges based on obviousness.
Potential Challenges
- Given the expiration of many related patents, competitors can develop similar compounds.
- Claim breadth may meet legal scrutiny if challenged on obviousness, especially given prior art on gepirone and similar compounds.
Conclusion & Key Takeaways
| Aspect |
Insights |
| Scope |
Focuses on methods of treatment and compositions using specific 5-HT1A receptor agonists, primarily gepirone derivatives, for neuropsychiatric conditions. |
| Claim Breadth |
Narrower than broad serotonergic agents but significant for approved or investigational compositions and regimens. |
| Patent Landscape |
Mature, with many related patents now expiring, reducing exclusivity for some compounds but maintaining protection on specific methods or formulations. |
| Competitive Positioning |
Useful for companies seeking to develop targeted serotonergic therapies with clear IP around specific compounds and treatment protocols. |
| Legal and Commercial Strategies |
Should monitor patent expiration timelines, consider freedom-to-operate analyses, and evaluate potential for patent challenges or licensing. |
FAQs
1. Does U.S. Patent 8,333,992 cover all 5-HT1A receptor agonists?
No. The claims are specific to certain compounds, primarily gepirone derivatives, and do not broadly encompass all 5-HT1A agonists.
2. Can other companies develop similar drugs without infringing this patent?
Potentially, if they use different compounds not covered by the claims or different methods of administration, but they must ensure their substitutes do not fall within the scope of claims.
3. How does patent expiration affect market exclusivity for gepirone-like drugs?
Most patents covering gepirone and similar agents are expiring or expired, opening opportunities for generic development and market competition.
4. What are the main challenges in patenting serotonergic agents?
The primary challenges include demonstrating non-obviousness amid extensive prior art, securing broad claims without overreach, and navigating overlapping patent rights.
5. How does this patent influence the development of new neuropsychiatric treatments?
It provides a protected platform for targeted therapies, but subsequent innovations need to clear existing patents or develop novel compounds and methods.
References
- U.S. Patent and Trademark Office (USPTO). Patent 8,333,992.
- FDA. Gepirone Approval Documents.
- Brunswick, M. "Serotonergic agents in neuropsychopharmacology," Neuropharmacology Journal, 2010.
- Gopalakrishnan, A. "Patent landscape of 5-HT1A receptor agonists," Pharmacology & Therapeutics, 2018.
- EPO and USPTO patent databases. Patent expiration and status data.
More… ↓
⤷ Start Trial
|
